USANA Health Sciences management commentary cites weaker Core Nutritional, Rise Wellness sales as drivers of Q3 2026 revenue decline

• USANA Health Sciences' management commentary reported third-quarter 2026 sales fell 4% to $206 million as Core Nutritional and Rise Wellness declines outweighed Hiya growth.
• Net loss attributable to USANA narrowed to $5.6 million from $6.5 million; adjusted EBITDA fell 13% to $12.1 million.
• Core Nutritional's operating margin rose to 4.1% from 1.2%, reflecting lower incentive costs, event expenses and employee compensation despite weaker sales.
• Hiya sales increased 2% to $32 million, supported by improving marketing traction and back-to-school demand; increased customer-acquisition spending pressured margins.
• Management corrected second-quarter adjusted EBITDA attributable to USANA to $21.7 million from $27.8 million, removing noncontrolling interests' share of an impairment add-back.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. USANA Health Sciences Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.